NCT04135417View on ClinicalTrials.gov

Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

May 15, 2021

Study Completion Date

March 2, 2022

Conditions
Renal FailureEnd Stage Renal DiseaseVascular AccessHemodialysis
Interventions
BIOLOGICAL

HAV

Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.

Trial Locations (2)

61-848

Szpital Kliniczny Przemienienia Pańskiego UM w Poznaniu, Klinika Chirurgii Ogólnej i Naczyń, Poznan

51-124

Wojewódzki Szpital Specjalistyczny we Wrocławiu, Oddział Chirurgii Naczyniowej, Wroclaw

Sponsors

Lead Sponsor

Humacyte, Inc.
All Listed Sponsors
lead

Humacyte, Inc.

INDUSTRY

NCT04135417 - Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis | Biotech Hunter | Biotech Hunter